RVPH

Reviva Pharmaceuticals (OTC: RVPH). Brilaroxazine for schizophrenia. First write-up June 2026.

Teva's Fingerprints on Reviva

Reviva pushed its Phase 3 back a year, and the stock is down ~27% since my June write-up. Two developments matter more: (1) a patent filing that stretches exclusivity to 2046 and (2) evidence Teva has studied brilaroxazine since 2023.

by Fajasy

Aug 20, 2026

RVPH

Phase 3 Drug Priced for Zero

Reviva trades below its cash and just dropped to the OTC market, but it owns a schizophrenia drug that topped Caplyta's Phase 3 numbers, the kind big pharma buys for billions

by Fajasy

Jun 18, 2026